KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Net Cash Flow (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Net Cash Flow for 6 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 84.83% year-over-year to $7.0 million, compared with a TTM value of -$3.2 million through Dec 2025, down 109.32%, and an annual FY2025 reading of -$3.2 million, down 109.32% over the prior year.
  • Net Cash Flow was $7.0 million for Q4 2025 at Aurinia Pharmaceuticals, down from $20.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $174.3 million in Q4 2021 and bottomed at -$115.8 million in Q1 2021.
  • Average Net Cash Flow over 5 years is -$9.6 million, with a median of -$6.2 million recorded in 2023.
  • Peak annual rise in Net Cash Flow hit 1768.08% in 2024, while the deepest fall reached 325.72% in 2024.
  • Year by year, Net Cash Flow stood at $174.3 million in 2021, then tumbled by 95.34% to $8.1 million in 2022, then crashed by 69.48% to $2.5 million in 2023, then skyrocketed by 1768.08% to $46.3 million in 2024, then plummeted by 84.83% to $7.0 million in 2025.
  • Business Quant data shows Net Cash Flow for AUPH at $7.0 million in Q4 2025, $20.2 million in Q3 2025, and -$13.4 million in Q2 2025.